Unit One

Biologic Development and Reproductive Anatomy

Puberty is the period of physical transition from childhood to sexual maturity, driven by complex neuroendocrine events. It encompasses both primary and secondary sex characteristic developments that follow a predictable, sequential timeline.

Neuroendocrine Pathway of Puberty

The initiation of pubertal maturation is governed by the hypothalamic-pituitary-gonadal (HPG) axis:

1. Hypothalamus: Secretes Gonadotropin-Releasing Hormone ($\text{GnRH}$).

2. Anterior Pituitary Gland: Responds to $\text{GnRH}$ by secreting Follicle-Stimulating Hormone ($\text{FSH}$) and Luteinizing Hormone ($\text{LH}$).

3. Gonads (Ovaries / Testes): Stimulated by $\text{FSH}$ and $\text{LH}$ to produce sex steroids: Estrogen in females and Testosterone in males.

4. Target Effects: Sex hormones stimulate target tissues, initiating internal and external physical pubertal changes.

Sex-Specific Hormonal Actions

• Females: Rising estrogen levels stimulate ovarian follicle maturation, endometrial lining proliferation, menarche, and eventual ovulatory cycles.

• Males: Rising testosterone levels promote testicular enlargement, spermatogenesis, increase in lean muscle mass, and rapid height growth.

• Both Sexes: Increased secretion of adrenal androgens stimulates pubic and axillary hair development, acne, body odor, and accelerated bone mineral density growth. While adrenals secrete small hormone quantities in prepubertal years, gonadal maturation drives the primary changes of puberty.

Primary vs. Secondary Sex Characteristics

• Primary Sex Characteristics: The internal and external structures and organs directly needed for biological reproduction (e.g., ovaries, uterus, vagina, testes, penis).

• Secondary Sex Characteristics: Physical developments resulting from hormonal changes that play no direct role in biological reproduction (e.g., voice change, body hair growth, breast enlargement, fat distribution patterns).

Sequences of Maturational Changes & Tanner Stages

Sexual maturity follows a predictable pattern, evaluated clinically using Tanner Stages (Sexual Maturity Rating) to monitor development.

• Girls Maturation Timeline: Begins with breast bud development and spans $1.5 \text{ to } 6 \text{ years}$ to reach full maturity. The usual sequence includes:

  1. Breast changes (thelarche).

  2. Rapid increase in height and weight.

  3. Growth of pubic hair (pubarche).

  4. Appearance of axillary hair.

  5. Menstruation (menarche).

  6. Abrupt deceleration of linear growth.

• Boys Maturation Timeline: Begins with testicular enlargement and spans $2 \text{ to } 5 \text{ years}$ to reach full maturity. The usual sequence includes:

  1. Enlargement of testicles.

  2. Growth of pubic hair, axillary hair, facial hair (upper lip), and body hair.

  3. Rapid increase in height.

  4. Changes in the larynx resulting in voice deepening.

  5. Nocturnal emissions (spermarche).

  6. Abrupt deceleration of linear growth.

Tanner Staging Criteria

Female Breast Development

• Stage 1: Prepubertal; elevation of papilla only.

• Stage 2 (Pubertal): Breast bud stage; small elevation area around papilla, enlargement of areolar diameter.

• Stage 3: Further enlargement of breast and areola with no separation of their contours.

• Stage 4: Projection of areola and papilla to form a secondary mound (may not occur in all girls).

• Stage 5: Mature configuration; projection of papilla only, caused by recession of the areola into the general breast contour.

Female Pubic Hair Development

• Stage 1 (Prepubertal): No pubic hair; essentially identical to childhood; no distinction between hair over pubis and abdomen.

• Stage 2: Sparse growth of long, straight, downy, slightly pigmented hair along labia; begins to appear on pubis between stages 2 and 3.

• Stage 3: Hair becomes darker, coarser, and curlier, spreading sparsely over the entire pubis in the typical female inverted triangle.

• Stage 4: Hair is denser, curled, and adult in distribution, but less abundant and strictly restricted to the pubic area.

• Stage 5: Adult in quantity, type, and pattern, spreading to the inner aspects of the thighs.

Male Genital and Pubic Hair Development

• Stage 1 (Prepubertal): No pubic hair; genitalia same size as early childhood.

• Stage 2 (Pubertal): Initial enlargement of scrotum and testes; reddening and textural changes of scrotal skin; sparse growth of long, straight, downy hair at base of penis.

• Stage 3: Initial enlargement of penis (mainly in length); testes and scrotum enlarge further; pubic hair darker, coarser, curlier, and spread sparsely over pubis.

• Stage 4: Increased penis size with growth in diameter and glans development; glans broader; scrotum darker; pubic hair adult in type, curled, abundant, but restricted to pubic area.

• Stage 5: Testes, scrotum, and penis adult in size and shape; pubic hair adult in quantity and pattern with spread to inner surface of thighs.

Female Reproductive System Anatomy

External Structures (The Vulva)

• Mons Pubis: Fatty tissue pad overlying the pubic symphysis.

• Labia Majora & Labia Minora: Protective skin folds surrounding the vestibule.

• Clitoris & Prepuce: Erectile tissue structure capped by a hood-like prepuce.

• Vestibule: Area enclosed by the labia minora containing the urethral orifice, vaginal orifice, and hymen.

• Gland Openings: Skene duct openings (paraurethral) and Bartholin gland openings (vulvovaginal lubricating glands).

• Fourchette & Perineal Body: Posterior junction of labia minora and muscular tissue base supporting the pelvic floor between vaginal orifice and anus.

Internal Structures & Supporting Ligaments

• Vagina & Cervix: Fibromuscular canal extending to the cervical os; fornices surround the projecting cervix.

• Uterus (Corpus & Endometrium): Hollow, thick-walled muscular organ supported by pelvic musculature (levator ani, urogenital diaphragm).

• Uterine Tubes (Fallopian Tubes) & Ovaries: Conduit for ovum transport and primary sites of oogenesis/steroidogenesis.

• Supporting Ligaments:

  • Round Ligaments: Keep uterus in an anteverted position.

  • Broad / Cardinal / Anterior Ligaments: Provide lateral pelvic wall anchorage.

  • Uterosacral Ligaments: Anchor cervix posteriorly to sacrum.

  • Ovarian & Infundibulopelvic Ligaments: Suspend ovaries relative to uterus and pelvic side wall.

• Posterior Cul-de-sac of Douglas: Peritoneal pouch situated between posterior uterine wall and rectum.

The Bony Pelvis

• Primary Functions:

  1. Protection of internal pelvic structures.

  2. Accommodation and containment of the growing fetus during pregnancy.

  3. Anchorage site for pelvic support muscles and ligaments.

• Anatomical Divisions:

  • False Pelvis: Upper cavity above pelvic brim (linea terminalis).

  • True Pelvis: Lower rigid curved canal (Inlet, Midpelvis, Outlet) through which fetus passes.

• Bony Structures: Innominates (Ilium, Ischium, Pubis), Sacrum (with sacral promontory), Coccyx, Sacroiliac joints, Acetabulum, Obturator foramen, Subpubic arch, and Ischial spines (key landmarks for fetal descent).

Breasts—Structure and Function

• Mammary Gland Microstructure: Composed of $15 \text{ to } 20$ lobes divided into lobules, which contain clusters of milk-secreting acini.

• Ductal System: Acini drain into ductules, which converge into lactiferous ducts ending at nipple pores.

• Montgomery Tubercles: Sebaceous glands scattered across the areola that secrete protective lubricating substances during lactation.

• Cooper's Ligaments: Suspensory fibrous bands anchoring breast tissue to the overlying dermis and underlying pectoralis major fascia.

• Hormonal Regulation: Estrogen promotes ductal proliferation; Progesterone stimulates acinar/lobular development.

Reproductive Physiology: Menstrual Cycle & Menopausal Transition

Menarche and Early Menstruation

• Definitions:

  • Puberty: Broad developmental transition to sexual reproduction.

  • Menarche: The first occurrence of menstruation.

• Hormonal Initiation: A gradual, progressive rise in gonadotropin ($\text{FSH}$ and $\text{LH}$) and estrogen secretion begins roughly $1 \text{ year}$ prior to menarche, establishing cyclic secretory rhythms.

• Early Menstrual Pattern: Early cycles post-menarche are typically irregular, unpredictable, painless, and anovulatory. Regular ovulatory cycles establish as feedback mechanisms mature, establishing a dominant estrogenic phase followed by a progesterone-dominant luteal phase.

The Menstrual Cycle

Menstruation is periodic uterine mucosal bleeding occurring roughly $14 \text{ days}$ after ovulation. The average cycle lasts $28 \text{ days}$ (Day 1 = first day of menses).

Interconnected Cycle Components

1. Hypothalamic-Pituitary Cycle:

   • Low circulating estrogen/progesterone levels stimulate hypothalamus to release $\text{GnRH}$.

   • $\text{GnRH}$ triggers anterior pituitary release of $\text{FSH}$ and $\text{LH}$.

2. Ovarian Cycle:

   • Follicular Phase: $\text{FSH}$ stimulates primary follicle growth into a mature Graafian follicle, which secretes increasing estrogen.

   • Ovulation: Rapid estrogen rise induces a massive surge of $\text{LH}$ (and $\text{FSH}$) at ~Day 14, causing follicle rupture and egg release.

   • Luteal Phase: Ruptured follicle wall transforms into the Corpus Luteum, secreting high Progesterone and moderate Estrogen. Lacking fertilization, corpus luteum degenerates, dropping hormone levels.

3. Endometrial Cycle:

   • Menstrual Phase (Days 1–5): Functional endometrial layer sheds.

   • Proliferative Phase (Days 5–14): Estrogen drives rapid endometrial cell regrowth.

   • Secretory Phase (Days 14–28): Progesterone causes tissue hypertrophy, vascular congestion, and glycogen storage for blastocyst implantation.

   • Ischemic Phase: Hormone withdrawal causes spiral artery vasospasm, tissue necrosis, and onset of menses.

Prostaglandins in Menstruation and Reproduction

Prostaglandins are oxygenated fatty acids produced by endometrial cells.

• Systemic Biological Activity: Active in cardiovascular, gastrointestinal, genitourinary, respiratory, and nervous systems; directly influence carbohydrate metabolism (glycolysis).

• Reproductive Functions:

  • Modulate smooth muscle contractility (uterine myometrial cramping).

  • Regulate tubal and uterine motility.

  • Induce follicular rupture (ovulation) and cervical mucus changes.

  • Essential for menstruation, spontaneous abortion, induced abortion, and the initiation/maintenance of labor.

Climacteric, Perimenopause, and Menopause

• Definitions:

  • Climacteric Transition: Broad developmental phase spanning initial ovarian function decline through cessation of menopausal symptoms.

  • Perimenopause: A preceding $4 \text{-year}$ period characterized by progressive ova depletion, declining estrogen, and irregular, anovulatory cycles.

  • Menopause: Permanent cessation of menses resulting from loss of ovarian follicular activity.

• Clinical Features:

  • Average age of onset is $51.4 \text{ years}$ (normal range: $35 \text{ to } 60 \text{ years}$).

  • Diagnostic Confirmation: Dated with clinical certainty only after 12 consecutive months of amenorrhea without other physiological causes.

Infertility: Assessment, Management, and Alternative Options

Infertility vs. Sterility

• Infertility: Inability to conceive after $1 \text{ year}$ of regular, unprotected sexual intercourse ($6 \text{ months}$ for women $\ge 35 \text{ years}$). Affects approximately $12\%$ of reproductive-age couples.

• Sterility: Absolute, irreversible incapacity to conceive biological offspring.

Nursing Care Framework Goals

When working with patients experiencing infertility, nursing interventions are centered around four primary goals:

1. Provide accurate, non-judgmental information regarding fertility, diagnostic testing, and treatment options.

2. Assist in identifying specific underlying etiology/factors contributing to infertility.

3. Provide comprehensive emotional, psychological, and spiritual support.

4. Guide and assist patients in exploring alternative paths to parenthood or childfree living.

Etiology and Associated Factors

Female Infertility Factors

• Ovarian Factors: Anovulation, polycystic ovarian syndrome (PCOS), premature ovarian insufficiency, hyperprolactinemia, thyroid dysfunction.

• Tubal and Peritoneal Factors: Pelvic adhesions, tubal occlusion/blockage, salpingitis, endometriosis, history of pelvic inflammatory disease (PID).

• Uterine Factors: Uterine leiomyomas (fibroids), endometrial polyps, congenital uterine anomalies (septate/bicornuate uterus), Asherman syndrome.

• Vaginal-Cervical Factors: Hostile cervical mucus, cervical stenosis, anti-sperm antibodies, altered vaginal pH.

Male Infertility Factors

• Hormonal Factors: Hypogonadotropic hypogonadism, pituitary tumors, endocrine disruption.

• Testicular Factors: Varicocele (most common reversible cause), cryptorchidism, trauma, orchitis, genetic disorders (Klinefelter syndrome).

• Sperm Transport Factors: Vas deferens obstruction, retrograde ejaculation, hypospadias, erectile dysfunction.

• Idiopathic Male Infertility: Sperm abnormalities without identifiable structural or endocrine etiology.

Transgender Infertility Issues

• Fertility Preservation: Gamete (oocyte or sperm) cryopreservation prior to gender-affirming hormone therapy (GAHT) or gonadectomy.

• Care Delivery: Transgender individuals with intact reproductive organs retain reproductive capacity. Healthcare requires interprofessional collaboration, staff education, and affirming, non-discriminatory care environments.

Diagnostic Assessments

• Female Diagnostics:

  • Ovulation Detection: Basal body temperature (BBT) charts, urinary $\text{LH}$ surge kits, serum progesterone levels.

  • Hormonal Analysis: $\text{FSH}$, $\text{LH}$, Anti-Müllerian Hormone (AMH), estradiol, thyroid-stimulating hormone (TSH), prolactin.

  • Imaging & Direct Procedures: Transvaginal ultrasonography, Endometrial biopsy, Hysterosalpingography (HSG) (radiopaque dye instillation to assess tubal patency and uterine cavity), Laparoscopy (direct surgical visualization of pelvic structures with peritoneal gas insufflation).

• Male Diagnostics:

  • Semen Analysis: Core assessment evaluating sperm count, concentration, motility, morphology, volume, and pH.

  • Endocrine & Imaging: Serum testosterone, $FSH$, $LH$, prolactin; scrotal/transrectal ultrasound.

Care Management Strategies

Psychosocial Support

Infertility induces significant psychological stress, grief, and self-esteem crises. Providers must deliver inclusive care, offer referrals for professional counseling, and connect clients with advocacy organizations like RESOLVE (National Infertility Association) and the American Society for Reproductive Medicine (ASRM).

Non-Medical Therapy and Lifestyle Modifications

• Nutrition & Weight: Achieving optimal BMI (weight extremes disrupt ovulatory drive).

• Behavioral Adaptations: Intercourse timing aligned with peak LH surge; avoidance of high heat exposure (hot tubs, saunas), tight underwear, alcohol, tobacco, and recreational drugs in males.

• Complementary Approaches: Acupuncture, stress reduction (mind-body therapy), and oral antioxidants (Vitamins E, C, selenium, zinc, CoQ10, ginseng).

Pharmacological Interventions

• Clomiphene Citrate: Selective estrogen receptor modulator; first-line ovulation induction agent.

• Menotropins & Follitropins: Human menopausal gonadotropins and recombinant $\text{FSH}$ to directly stimulate follicular development.

• Human Chorionic Gonadotropin (hCG / Gonadotropins): Administered to mimic $\text{LH}$ surge and induce final oocyte maturation/ovulation.

• GnRH Agonists & Antagonists: Suppress endogenous gonadotropin production to prevent premature LH surges during controlled ovarian hyperstimulation.

• Progesterone: Luteal phase support following ovulation induction or ART cycles.

• Metformin: Insulin-sensitizing agent used off-label to restore ovulatory cycles in PCOS.

• Letrozole: Aromatase inhibitor used for ovulation induction.

Assisted Reproductive Technologies (ART) & Alternatives

• In Vitro Fertilization-Embryo Transfer (IVF-ET): Oocytes harvested, fertilized with sperm in vitro, and embryos transferred into the uterus.

• Gamete Intrafallopian Transfer (GIFT): Unfertilized oocytes and washed sperm combined and surgically placed into fallopian tube.

• Zygote Intrafallopian Transfer (ZIFT): In vitro fertilized zygote transferred directly into the fallopian tube.

• Therapeutic Donor Insemination (TDI) & Ovum Transfer: Donor sperm or donor eggs used when patient gametes are non-viable.

• Surrogacy / Gestational Carrier: Third-party individual carries fetus to term.

• Preimplantation Genetic Diagnosis (PGD): Genetic screening of embryos prior to transfer.

• Cryopreservation: Freezing of surplus embryos, oocytes, or sperm.

• Adoption: Alternative non-biological family building pathway.

• Risks & Ethical Considerations: Risk of Ovarian Hyperstimulation Syndrome (OHSS), high incidence of multiple gestations, complex legal parentage status of donors/surrogates, moral distress, and high financial costs.

Sexually Transmitted and Vaginal Infections

Overview and Risk Assessment

More than 25 infectious organisms are transmitted sexually, affecting roughly 19 million people annually in the United States. Prevention strategies focus on Primary (preventing acquisition via education and barrier methods) and Secondary (early screening and treatment).

The Five Ps of Sexual History Assessment

1. Partners: Number and gender of sexual partners.

2. Practices: Types of sexual activity (vaginal, oral, anal).

3. Protection from STIs: Frequency and consistency of condom/barrier use.

4. Past History of STIs: Prior history of infections or treatment.

5. Prevention of Pregnancy: Contraceptive methods utilized.

Bacterial Sexually Transmitted Infections

Chlamydia (Chlamydia trachomatis)

• Features: Most frequently reported STI in the US. Infections are typically silent (asymptomatic) but highly destructive.

• Clinical Signs: Cervical discharge (mucoid/purulent), dysuria, intermenstrual or postcoital spotting.

• Diagnostics: Nucleic Acid Amplification Testing (NAAT), DNA probes, or cultures. Screen all pregnant clients at initial prenatal visit and re-screen at 36 weeks gestation for high-risk clients ($<25 \text{ years}$, new or multiple partners).

• Pharmacological Treatment:

  • Non-Pregnant: Azithromycin (1 g orally single dose) OR Doxycycline (100 mg orally BID for 7 days).

  • Pregnant / Lactating: Azithromycin (1 g orally single dose) OR Amoxicillin (500 mg orally TID for 7 days).

  • Note: Sexual partners must be treated concurrently.

• Complications: Pelvic Inflammatory Disease (PID), tubal factor infertility, ectopic pregnancy, neonatal conjunctivitis or pneumonia, stillbirth, preterm labor.

Gonorrhea (Neisseria gonorrhoeae)

• Features: Oldest communicable STI, affecting ~$1,568,000 \text{ clients/year}$ with increasing antimicrobial resistance. Transmitted via genital, oral, or anal contact; age is the primary risk factor.

• Clinical Signs: Often asymptomatic in females. Manifests with greenish-yellow endocervical discharge, dysuria, dysmenorrhea, or pelvic pain. Rectal involvement causes purulent anal discharge, rectal bleeding, pain, and tenesmus.

• Diagnostics & Treatment: Culture or NAAT. Treated with Ceftriaxone IM in combination with treatment for co-occurring Chlamydia. Partners must be treated; abstain or use condoms until dual repeat cultures test negative.

• Pregnancy & Neonatal Impact: Premature rupture of membranes (PROM), chorioamnionitis, preterm birth, neonatal sepsis, intrauterine growth restriction (IUGR). Causes Ophthalmia Neonatorum (neonatal blindness). All newborns receive Erythromycin Ophthalmic Ointment prophylaxis at birth.

Syphilis (Treponema pallidum)

• Features: Caused by a motile spirochete entering via micro-abrasions or transplacentally.

• Clinical Stages:   

  

  • Primary Stage ($5 \text{ to } 90 \text{ days}$ post-exposure): Characterized by a single, hard, painless ulcerated lesion (chancre).

  • Secondary Stage ($6 \text{ weeks to } 6 \text{ months}$ post-exposure): Generalized maculopapular rash (characteristically on palms and soles), fever, condylomata lata, lymphadenopathy, malaise.

  • Tertiary Stage (Untreated late stage): Severe cardiovascular, neurological, musculoskeletal, or multiorgan systemic complications; potentially fatal.

• Diagnostics: Serologic screening with VDRL or RPR tests, confirmed by treponemal antibody tests (FTA-ABS) or lesion darkfield microscopy.

• Treatment: Penicillin G (parenteral) is the drug of choice; Erythromycin used as alternative. Treatment prior to 16 weeks gestation successfully prevents fetal congenital syphilis, hydrocephalus, cataracts, and stillbirth.

Pelvic Inflammatory Disease (PID)

• Etiology: Polymicrobial ascending infection from the lower genital tract to the upper reproductive system (causing salpingitis and endometritis). Most commonly caused by N. gonorrhoeae and C. trachomatis.

• Clinical Risks: High incidence of ectopic pregnancy, tubal factor infertility, and chronic pelvic pain.

• Management: Parenteral or oral broad-spectrum antibiotic therapy, bed rest, analgesia, and patient education.

Viral Sexually Transmitted Infections

Herpes Simplex Virus (HSV)

• Features: Chronic, recurrent viral infection without a cure. HSV-1 is typically non-sexual/oral; HSV-2 is typically sexually transmitted/genital.

• Signs: Clusters of painful, fluid-filled vesicular genital lesions that rupture into shallow ulcers.

• Treatment: Antiviral therapy (Acyclovir) reduces symptom duration and viral shedding. Active genital lesions present at the onset of labor warrant an immediate Cesarean Section to prevent catastrophic neonatal herpes transmission.

Human Papillomavirus (HPV)

• Features: Most common viral STI; heightened prevalence during pregnancy.

• Signs: Soft, fleshy, single or clustered papillary growths with a cauliflower-like appearance (condylomata acuminata), associated with itching, discharge, and postcoital bleeding.

• Prevention & Treatment: Gardasil or Cervarix vaccines administered in a 3-dose series (recommended between ages 9 and 26 years prior to sexual debut). Lesion management focuses on topical removal (trichloroacetic acid) and symptom relief.

Viral Hepatitis

• Hepatitis A Virus (HAV): Transmitted primarily via fecal-oral route, contaminated food/water, or close physical contact. Prevented effectively via HAV vaccination; managed with supportive care.

• Hepatitis B Virus (HBV): Transmitted parenterally, perinatally, or intimate contact. Most threatening hepatitis virus to fetus/neonate. Screened on birth facility admission. Managed with maternal HBV vaccine series prevention and post-exposure neonatal immunoglobulins.

• Hepatitis C Virus (HCV): Most common bloodborne infection in the US, transmitted via blood exposure (major risk factor: IV drug use). No vaccine available.

Human Immunodeficiency Virus (HIV)

• Features: Transmitted via body fluid exchange; induces profound cellular immunosuppression (AIDS).

• Symptoms: Acute retroviral syndrome (fever, headache, night sweats, lymphadenopathy, myalgias, rash, sore throat, weight loss).

• Screening: Voluntary antibody screening (rapid testing preferred) recommended for all pregnant clients.

• Pregnancy Management: Prophylactic Triple-Drug Antiretroviral Therapy (ART) reduces perinatal transmission rates to $<1\%$. Mode of delivery (Cesarean vs. Vaginal) is dictated by maternal viral load near term.

Zika Virus

• Features: Transmitted via Aedes mosquito bites and sexual contact via semen.

• Perinatal Risk: Infection during pregnancy causes severe congenital fetal brain anomalies, notably microcephaly.

• Prevention: Avoid travel to endemic regions (including southeastern US) and enforce condom use if male partner is potentially exposed.

Vaginal Infections & Group B Streptococcus

Bacterial Vaginosis (BV)

• Features: Synergistic alteration of vaginal flora where normal hydrogen peroxide-producing lactobacilli are replaced by high concentrations of anaerobic bacteria.

• Signs: Profuse, thin, white/gray/milky discharge with a distinct "fishy" odor. Microscopic identification reveals clue cells.

• Pregnancy Risk: Directly associated with premature rupture of membranes and preterm labor.

• Treatment: Oral or topical Metronidazole (Flagyl).

Candidiasis (Candida albicans)

• Features: Vulvovaginal fungal yeast infection; second most common cause of vaginal inflammation.

• Predisposing Factors: Broad-spectrum antibiotic use, diabetes mellitus, pregnancy, obesity, high intake of refined sugars, corticosteroid therapy, immunosuppression.

• Signs: Thick, white, curd-like ("cottage cheese") vaginal discharge with intense vulvar pruritus, dyspareunia, and erythema.

• Treatment: Topical or oral antifungal agents (Miconazole, Clotrimazole).

Trichomoniasis (Trichomonas vaginalis)

• Features: Common protozoan STI causing lower genital tract infection.

• Signs: Yellowish-greenish, frothy, copious, malodorous discharge accompanied by vulvar irritation and a classic "strawberry cervix" appearance.

• Treatment: Metronidazole or Tinidazole orally. Sexual partners must be treated concurrently.

Group B Streptococcus (GBS)

• Features: Normal vaginal flora in non-pregnant individuals, but a leading cause of severe neonatal morbidity and mortality (sepsis, pneumonia, meningitis).

• Screening: Universal screening via rectovaginal culture performed at 35 to 37 weeks gestation.

• Intrapartum Management: Clients testing positive (or positive rapid PCR at delivery) receive Intrapartum Antibiotic Prophylaxis (IAP) using IV antibiotics during labor.

Patient Teaching for Infection Prevention

• Practice rigorous genital hygiene; void before and after sexual intercourse.

• Choose breathable cotton underwear and hosiery; avoid tight-fitting trousers or synthetic garments.

• Select cloth car seat covers rather than heat-retaining vinyl.

• Promptly change out of damp exercise clothes or wet swimwear.

• Avoid bubble baths, bath salts, scented/colored toilet paper, and feminine hygiene sprays.

• Increase dietary consumption of yogurt or active-culture milk to support lactobacilli flora; never douche.